29 reports of this reaction
5.1% of all ACETAMINOPHEN, IBUPROFEN reports
#3 most reported adverse reaction
THERAPEUTIC PRODUCT EFFECT INCOMPLETE is the #3 most commonly reported adverse reaction for ACETAMINOPHEN, IBUPROFEN, manufactured by WALGREENS. There are 29 FDA adverse event reports linking ACETAMINOPHEN, IBUPROFEN to THERAPEUTIC PRODUCT EFFECT INCOMPLETE. This represents approximately 5.1% of all 567 adverse event reports for this drug.
Patients taking ACETAMINOPHEN, IBUPROFEN who experience therapeutic product effect incomplete should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THERAPEUTIC PRODUCT EFFECT INCOMPLETE is moderately reported among ACETAMINOPHEN, IBUPROFEN users, representing a notable but not dominant share of adverse events.
In addition to therapeutic product effect incomplete, the following adverse reactions have been reported for ACETAMINOPHEN, IBUPROFEN:
The following drugs have also been linked to therapeutic product effect incomplete in FDA adverse event reports:
THERAPEUTIC PRODUCT EFFECT INCOMPLETE has been reported as an adverse event in 29 FDA reports for ACETAMINOPHEN, IBUPROFEN. This does not prove causation, but indicates an association observed in post-market surveillance data.
THERAPEUTIC PRODUCT EFFECT INCOMPLETE accounts for approximately 5.1% of all adverse event reports for ACETAMINOPHEN, IBUPROFEN, making it one of the most commonly reported side effect.
If you experience therapeutic product effect incomplete while taking ACETAMINOPHEN, IBUPROFEN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.